{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:51:56Z","timestamp":1770288716944,"version":"3.49.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Limited data compared antiarrhythmic drugs (AADs) with concomitant non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients, hence the aim of the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>National health insurance database were retrieved during 2012\u201317 for study. We excluded patients not taking AADs, bradycardia, heart block, heart failure admission, mitral stenosis, prosthetic valve, incomplete demographic data, and follow-up &amp;lt;3 months. Outcomes were compared in Protocol 1, dronedarone vs. non-dronedarone; Protocol 2, dronedarone vs. amiodarone; and Protocol 3, dronedarone vs. propafenone. Outcomes were acute myocardial infarction (AMI), ischaemic stroke\/systemic embolism, intracranial haemorrhage (ICH), major bleeding, cardiovascular death, all-cause mortality, and major adverse cardiovascular event (MACE) (including AMI, ischaemic stroke, and cardiovascular death). In Protocol 1, 2298 dronedarone users and 6984 non-dronedarone users (amiodarone = 4844; propafenone = 1914; flecainide = 75; sotalol = 61) were analysed. Dronedarone was associated with lower ICH (HR = 0.61, 95% CI = 0.38\u20130.99, P = 0.0436), cardiovascular death (HR = 0.24, 95% CI = 0.16\u20130.37, P &amp;lt; 0.0001), all-cause mortality (HR = 0.33, 95% CI = 0.27\u20130.42, P &amp;lt; 0.0001), and MACE (HR = 0.56, 95% CI = 0.45\u20130.70, P &amp;lt; 0.0001). In Protocol 2, 2231 dronedarone users and 6693 amiodarone users were analysed. Dronedarone was associated with significantly lower ICH (HR = 0.53, 95%=CI 0.33\u20130.84, P = 0.0078), cardiovascular death (HR = 0.20, 95% CI = 0.13\u20130.31, P &amp;lt; 0.0001), all-cause mortality (HR 0.27, 95% CI 0.22\u20130.34, P &amp;lt; 0.0001), and MACE (HR = 0.53, 95% CI = 0.43\u20130.66, P &amp;lt; 0.0001), compared with amiodarone. In Protocol 3, 812 dronedarone users and 2436 propafenone users were analysed. There were no differences between two drugs for primary and secondary outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The use of dronedarone with NOACs was associated with cardiovascular benefits in an Asian population, compared with non-dronedarone AADs and amiodarone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euad083","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T16:29:21Z","timestamp":1680280161000},"source":"Crossref","is-referenced-by-count":8,"title":["Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-4369","authenticated-orcid":false,"given":"Victor Chien-Chia","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9437-5350","authenticated-orcid":false,"given":"Chun-Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6718-750X","authenticated-orcid":false,"given":"Yu-Chang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Tzu","family":"Tu","sequence":"additional","affiliation":[{"name":"Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-7238","authenticated-orcid":false,"given":"Yu-Tung","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-3221","authenticated-orcid":false,"given":"Chien-Hao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan City , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-1295","authenticated-orcid":false,"given":"Shao-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic and Vascular Surgery, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan City , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-5730","authenticated-orcid":false,"given":"Chang-Fu","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan City , Taiwan"},{"name":"Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham , Nottingham , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-3711","authenticated-orcid":false,"given":"Kuo-Chun","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-2344","authenticated-orcid":false,"given":"Shang-Hung","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"},{"name":"Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Medical Center , No. 5 Fuxing Street, Guishan District, Taoyuan City 33305 , Taiwan"},{"name":"Graduate Institute of Nursing, Chang Gung University of Science and Technology , Taoyuan City , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"2023053009411628600_euad083-B1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023053009411628600_euad083-B2","first-page":"1764","article-title":"Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"2023053009411628600_euad083-B3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"2023053009411628600_euad083-B4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter","volume":"357","author":"Singh","year":"2007","journal-title":"N Engl J Med"},{"key":"2023053009411628600_euad083-B5","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"Kober","year":"2008","journal-title":"N Engl J Med"},{"key":"2023053009411628600_euad083-B6","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMoa1109867","article-title":"Dronedarone in high-risk permanent atrial fibrillation","volume":"365","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2023053009411628600_euad083-B7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 Focused update consensus guidelines of the Asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"2023053009411628600_euad083-B8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2023053009411628600_euad083-B9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-pacific expert consensus paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemost"},{"key":"2023053009411628600_euad083-B10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2023053009411628600_euad083-B11","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2023053009411628600_euad083-B12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/europace\/euab200","article-title":"Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST\u2014AFNET 4 trial","volume":"24","author":"Metzner","year":"2022","journal-title":"Europace"},{"key":"2023053009411628600_euad083-B13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ahj.2018.06.018","article-title":"Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs","volume":"205","author":"Friberg","year":"2018","journal-title":"Am Heart J"},{"key":"2023053009411628600_euad083-B14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.11.133","article-title":"Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany","volume":"278","author":"Ehrlich","year":"2019","journal-title":"Int J Cardiol"},{"key":"2023053009411628600_euad083-B15","first-page":"890","article-title":"Risk of cardiovascular events, stroke, congestive heart failure, interstitial lung disease, and acute liver injury: dronedarone versus amiodarone and other antiarrhythmics","volume":"6","author":"Gao","year":"2013","journal-title":"J Atr Fibrillation"},{"key":"2023053009411628600_euad083-B16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.clinthera.2014.07.013","article-title":"Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion","volume":"36","author":"Chun","year":"2014","journal-title":"Clin Ther"},{"key":"2023053009411628600_euad083-B17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197352","article-title":"Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients","volume":"13","author":"Gwag","year":"2018","journal-title":"PLoS One"},{"key":"2023053009411628600_euad083-B18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40256-020-00454-6","article-title":"Safety and effectiveness of rivaroxaban in combination with Various antiarrhythmic drugs in patients with non-permanent atrial fibrillation","volume":"21","author":"Chiou","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2023053009411628600_euad083-B19","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of Major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"2023053009411628600_euad083-B20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amjcard.2021.08.015","article-title":"Risk of Major bleeding in patients with atrial fibrillation taking dronedarone in combination with a direct acting oral anticoagulant (from a U.S. Claims database)","volume":"159","author":"Gandhi","year":"2021","journal-title":"Am J Cardiol"},{"key":"2023053009411628600_euad083-B21","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. Warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"2023053009411628600_euad083-B22","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"2023053009411628600_euad083-B23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am Heart J"},{"key":"2023053009411628600_euad083-B24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euac062","article-title":"Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET\/EHRA consensus conference","volume":"25","author":"Schnabel","year":"2022","journal-title":"Europace"},{"key":"2023053009411628600_euad083-B25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/07853890.2010.538431","article-title":"The pharmaceutical pipeline for atrial fibrillation","volume":"43","author":"Santangeli","year":"2011","journal-title":"Ann Med"},{"key":"2023053009411628600_euad083-B26","article-title":"Drug interaction study with dabigatran etexilate and dronedarone in healthy subjects"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/5\/euad083\/50484875\/euad083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/5\/euad083\/50484875\/euad083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:42:05Z","timestamp":1685439725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad083\/7097999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad083","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,3,31]]},"article-number":"euad083"}}